VIROTECH Diagnostics GmbH – 30 years of system diagnostics
Virotech – the emergence of a concept...
A good idea and creative energy have always made it possible to create something new and innovative. That has been the case in 1986 when a virologist and a marketing expert decided to found a diagnostics company in Rüsselsheim. The idea was to develop ELISAs that prove IgG and IgM antibodies of numerous infectious diseases separately. In doing so, as many of the then new ELISAs should be processed with standardized reagents and standardized incubation periods.
The product concept was supposed to facilitate workflow for the customers: system diagnostics.
When the newly founded company was entered in the commercial register, the judge in charge refused the name Virotech GmbH because it was too generic and thusly gave the young company an indirect present. According to the founding idea an affix to the name was generated: the Virotech Systemdiagnostika GmbH was born.
Virotech Systemdiagnostika GmbH
The freshly founded company grew steadily. In 1987 it managed to gain venture capital for its development. In 1988/89 the federal government funded the development of an antigen production and a quantification system.
In 1991, Virotech Systemdiagnostika finally crossed the threshold into profitability. The next burst of growth followed in 1993 when Genzyme, one of the biggest American biotechnology corporations, showed interest in the successful Virotech Systemdiagnostika and acquired it.
Virotech Systemdiagnostik became Genzyme Virotech and had access to all resources of Genzyme. Meanwhile, Genzyme Virotech remained an independently operating company catering to the needs of its mostly European customers.
Starting in 1998, cost-cutting programs of health insurance companies in several European countries reduced sales quantities and realizable prices.
Many diagnostics companies had to face red numbers and closings. Genzyme Virotech, however, had been expanding its own product portfolio and taken over the distribution of other companies’ products.
In 2000, Genzyme Virotech acquired the bioline EcoBlot of Biosens and integrated it into system diagnostics in 2002.
Further development resulted in the product line LINE with innovative products such as EBV LINE with double cut-off or the Borrelia LINE with in vivo-expressed antigens.
A turning point was reached on February 1st, 2011. Due to a change in corporate strategy and a focus on the core business, Genzyme Virotech GmbH as a part of Genzyme diagnostics was sold to the Japanese corporation Sekisui Chemical. Since then, it has been part of the Sekisui Chemical group. The acquisition allowed for the retention of the successful business model and access to new markets, now under the name of Sekisui Virotech GmbH.
VIROTECH Diagnostics GmbH
VIROTECH Diagnostics GmbH emerged from Sekisui Virotech GmbH in December of 2016. Since then, we have been operating as a medium-sized Germany company with more than 30 years of experience in diagnostics again.
The foundation of our market success is the strict perpetuation of the system diagnostics concept and the steady revision and extension of our ELISA and Immunoblot product lines. Besides our in-house developed and manufactured products, VIROTECH Diagnostics GmbH is very successful in distributing 15 premium product lines from Europe, America, and Australia. VIROTECH Diagnostics GmbH products are sold in more than 30 countries worldwide. Sales expand steadily with new distributors in more countries around the world. In the future we will continue to provide you with high quality, customer-oriented service, and innovative products.
We are looking forward to our continuous successful cooperation with you.